EHDP

• Parasympatholytics
• ATC:G04BD02

• Acetodiphosphonic acid
• Acide etidronique [INN-French]
• Acido etidronico [INN-Spanish]
• Acidum etidronicum [INN-Latin]
• Cintichem Technetium 99m Hedspa
• Dequest 2010
• Dequest 2015
• Dequest Z 010
• Didronel
• Didronel IV
• EHDP
• Etidronate Disodium
• Etidronic acid
• Etidronic acid [USAN:BAN:INN]
• Etidronsaeure
• Ferrofos 510
• HEDP
• Hydroxyethanediphosphonic acid
• MPI Stannous Diphosphonate
• Osteoscan
• Oxyethylidenediphosphonic acid
• Turpinal SL

• No information avaliable

C₂₄H₂₅NO₄

http://www.rxlist.com/cgi/generic3/flavoxate.htm

No information avaliable

391.46 g/mol

No information avaliable

10 mg/L

Solid

4.636

Tablets (100 mg)

For symptomatic relief of dysuria, urgency, nocturia, suprapubic pain, frequency and incontinence as may occur in cystitis, prostatitis, urethritis, urethrocystitis/urethrotrigonitis.

Flavoxate is a spasmolytic flavone derivative that acts by relaxing the smooth muscle in the urinary tract. Flavoxate is a competitive muscarinic receptor antagonist indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency. Muscarinic receptors play an important role in several major cholin-ergically mediated functions, including contractions of urinary bladder smooth muscle and stimulation of salivary secretion.

Well absorbed from gastrointestinal tract.

The oral LD50 for flavoxate HCl in rats is 4273 mg/kg. The oral LD50 for flavoxate HCl in mice is 1837 mg/kg. Symptoms of overdose include convulsions, decreased ability to sweat, (warm, red skin, dry mouth, and increased body temperature), hallucinations, increased heart rate and blood pressure, and mental confusion.

Humans and other mammals